Quest Diagnostics is set to offer an FDA-cleared blood test for Alzheimer’s disease developed by Fujirebio. Building on its pioneering AD-Detect™ product line, the test will be available for clinical and research use as soon as this summer, marking a significant advancement in assessing symptomatic patients.